EDGAR·FLOW

Kyverna Therapeutics, Inc. — Form 8-K

Filed September 24, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
Kyverna announced positive one-year topline data from KYSA-8 (26 SPS patients) showing sustained 49% median improvement in timed 25-foot walk, 95% maintained benefit, 92% remained off chronic immunotherapies, with no high-grade CRS/ICANS/IEC-HS. KYSA-6 Phase 2 (7 gMG patients) showed durable responses sustained to 1.5 years, 100% off immunosuppressants at 24 weeks, 86% off at last follow-up. Rolling BLA submission on track for Q4 2026; Phase 3 enrollment expected complete mid-2027.
Why this rating

Late-stage clinical milestone—positive durability data de-risks regulatory approval path for lead program; BLA filing Q4 2026 imminent. Highly significant relative to $64.5M market cap and pre-revenue biotech profile. Addresses largest unmet need (SPS: zero approved therapies); first-in-class CAR T for autoimmune disease. Near-term binary: regulatory approval probability materially increased.

Tradability signal
NO TRADE

No trade: positive news with only -1.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.19% over 4 hrs, n=109). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$7.70 ▼ 1.41%
at our read · unknown
$7.81
+10 min · unknown
$7.38 ▼ 5.44%
+30 min · unknown
$7.07 ▼ 9.48%
+1 hr · unknown
$6.80 ▼ 12.93%
+4 hrs · unknown
$6.95 ▼ 11.01%

The stock had already moved +1.43% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ KYTX · stock on Yahoo Finance ↗

See more from September 24, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.